The Latest in Rapamycin Research in Humans (15 Longevity Studies)

Not many compounds actually extend life in healthy animals, but rapamycin is indeed one of them. Researchers report that its mechanism of action, the mechanistic target of rapamycin (known as mTOR), is linked to five of twelve hallmarks of aging. I hope you enjoy my content and find it interesting or informative, if so, please consider supporting the channel by using one of the affiliate links below: * Buy me a Kofi: https://ko-fi.com/mynmnexperiment * Patreon: https://bit.ly/3hhfjl5 * SubscribeStar: https://bit.ly/3psYo23 ProHealth 15% Discount Code: MYNMN (https://www.prohealth.com/) Renue by Science 10% Discount Code: MYNMN (https://renuebyscience.com/?rfsn=5692699.331801&coupon-code=MYNMN) Renue by Science 15% Subscription Service Discount Code: MYNMNSUB DoNotAge 10% Discount Code: MYNMN (https://bit.ly/2VBDgNt) Youth & Earth 15% Discount Code: MYNMN (https://youthandearth.com?sca_ref=3766764.knrWl4O3cB) Please note that the links above are affiliate links, which means that if you use the code, I will receive a small commission, and if you do, may I say many thanks I advance for your support. My Current Anti-Aging Protocol: • 1.5 grams of an NADBooster (https://bit.ly/3c2Fxt8) • 1.5 grams of Trans-resveratrol (Tue, Thu & Sat) (https://bit.ly/3yxeqy2) • 500mg Metformin • 1.5 grams of TMG (https://bit.ly/3oe1Ted) • 5,000 IU (International Units) of vitamin D3 (https://bit.ly/3P32hYH) • 120 mcg (micrograms) of vitamin K2 (Mk 7) (https://bit.ly/3PhkBgn) • 250mg Magnesium (L-Threonate) (https://bit.ly/3O4pZ5o) • 200mg high molecular weight hyaluronic acid (https://bit.ly/3P0Z4c2) • 2,400mg of Fisetin, on the 1st, 2nd & 3rd of each month (https://bit.ly/3P2rSB0) • 2,400mg of Quercetin, on the 1st, 2nd & 3rd of each month (https://bit.ly/3IzulAy) • Quercetin & Fisetin Periodic Dosing (https://bit.ly/3mw1IgN) • 81mg of aspirin (https://bit.ly/3uFjtem) • 800mg SIRT6 Activator (https://bit.ly/3MyfA4J) • 600mg DIM (https://bit.ly/3ZX9NsG) • 800mg GlyNAC (https://shorturl.ac/7b75r) • 5mg of Creatine (1 month on, 2 months off) Links: [1] Papadopoli, D., Boulay, K., Kazak, L., Pollak, M., Mallette, F. A., Topisirovic, I., & Hulea, L. (2019). mTOR as a central regulator of lifespan and aging. F1000Research, 8. [2] Lin, Y., Chen, T., Chen, J., Fang, Y., & Zeng, C. (2021). Endogenous Aβ induces osteoporosis through an mTOR-dependent inhibition of autophagy in bone marrow mesenchymal stem cells (BMSCs). Annals of Translational Medicine, 9(24). [3] Querfurth, H., & Lee, H. K. (2021). Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration. Molecular neurodegeneration, 16(1), 44. [4] Sciarretta, S., Forte, M., Frati, G., & Sadoshima, J. (2018). New insights into the role of mTOR signaling in the cardiovascular system. Circulation research, 122(3), 489-505. [5] Sabatini, D. M. (2006). mTOR and cancer: insights into a complex relationship. Nature Reviews Cancer, 6(9), 729-734. [6] Kraig, E., Linehan, L. A., Liang, H., Romo, T. Q., Liu, Q., Wu, Y., … & Kellogg Jr, D. L. (2018). A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. Experimental gerontology, 105, 53-69. [7] Palma, J. A., Martinez, J., Millar Vernetti, P., Ma, T., Perez, M. A., Zhong, J., … & Kaufmann, H. (2022). mTOR inhibition with Sirolimus in multiple system atrophy: a randomized, double‐blind, placebo‐controlled futility trial and 1‐year biomarker longitudinal analysis. Movement Disorders, 37(4), 778-789. [8] Minturn, R. J., Bracha, P., Klein, M. J., Chhablani, J., Harless, A. M., & Maturi, R. K. (2021). Intravitreal sirolimus for persistent, exudative age-related macular degeneration: a Pilot Study. International Journal of Retina and Vitreous, 7, 1-10. [9] Petrou, P. A., Cunningham, D., Shimel, K., Harrington, M., Hammel, K., Cukras, C. A., … & Wong, W. T. (2015). Intravitreal sirolimus for the treatment of geographic atrophy: results of a phase I/II clinical trial. Investigative ophthalmology & visual science, 56(1), 330-338. [10] Seyfarth, H. J., Hammerschmidt, S., Halank, M., Neuhaus, P., & Wirtz, H. R. (2013). Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial. Pulmonary circulation, 3(3), 632-638. [11] Bruyn, G. A., Tate, G., Caeiro, F., Maldonado-Cocco, J., Westhovens, R., Tannenbaum, H., … & RADD Study Group. (2008). Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study. Annals of the rheumatic diseases, 67(8), 1090-1095. #rapamycin #longevitysupplements #longevity